Aerami Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched1 / 4
Sections to complete：02
01 / WHAT IT BUILT
What the company did
Development of inhaled treatments for chronic diseases.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Operations ended
Aerami Therapeutics was reported closed in August 2024; public records did not describe a more specific ending process.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
In March 2022, Aerami and FoxWayne Enterprises Acquisition Corp. mutually terminated their SPAC merger agreement, citing unfavorable market conditions.
- 02
In May 2023, the company announced the death of its CEO, Steve Thornton, and appointed interim leadership as it advanced its lead asset AER-901 (inhaled imatinib) toward Phase 2 trials.
- 03
In 2024, Aerami Therapeutics shut down; its last public announcement was in May 2024.